Simultaneous multiple interaction T-cell engaging (SMITE) bispecific antibodies overcome bispecific T-cell engager (BiTE) resistance via CD28 co-stimulation

Leukemia. 2018 May;32(5):1239-1243. doi: 10.1038/s41375-018-0014-3. Epub 2018 Jan 31.
No abstract available

Publication types

  • Letter
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Bispecific / pharmacology
  • Antibodies, Bispecific / therapeutic use*
  • CD28 Antigens / metabolism*
  • CD3 Complex / metabolism*
  • Cell Line
  • Costimulatory and Inhibitory T-Cell Receptors*
  • Drug Resistance
  • Humans
  • Immunotherapy, Adoptive / methods*
  • Lymphocyte Activation / immunology*
  • Neoplasms / drug therapy
  • Neoplasms / immunology
  • T-Lymphocytes / immunology

Substances

  • Antibodies, Bispecific
  • CD28 Antigens
  • CD3 Complex
  • Costimulatory and Inhibitory T-Cell Receptors
  • blinatumomab